Semaglutide is a once-weekly (OW) subcutaneous (s.c.)human long-acting GLP-1 RA that was approved by the European Medicines Agency (EMA) in 2018 for the treatment of insufficiently controlled T2DM as an adjunct therapy to diet and exercise, either as a second-line monotherapy or as an add-on treatment [15]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.